Christopher Baker
University of Toronto
14 Papers
47 Citations
Christopher Baker is an academic researcher from University of Toronto. The author has contributed to research in topics: Chylomicron & Insulin resistance. The author has an hindex of 14, co-authored 14 publications. Previous affiliations of Christopher Baker include University of Nebraska–Lincoln & Hospital for Sick Children.
Chat about Author
Papers
Fructose: a highly lipogenic nutrient implicated in insulin resistance, hepatic steatosis, and the metabolic syndrome
TL;DR: This review highlights recent findings in fructose feeding studies in both human and animal models with a focus on the molecular and biochemical mechanisms that underlie the development of insulin resistance, hepatic steatosis, and the metabolic syndrome.
418
AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism
Stephen L. Pinkosky,Sergey Filippov,Rai Ajit K. Srivastava,Jeffrey C. Hanselman,Cheryl D. Bradshaw,Timothy R. Hurley,Clay T. Cramer,Mark A. Spahr,Ashley F. Brant,Jacob L. Houghton,Christopher Baker,Mark Naples,Khosrow Adeli,Roger S. Newton +13 more
TL;DR: ETC-1002 treatment reduced circulating proatherogenic lipoproteins, hepatic lipids, and body weight in a hamster model of hyperlipidemia, and it reduced body weight and improved glycemic control in a mouse model of diet-induced obesity.
210
Metabolic Effects of Dietary Cholesterol in an Animal Model of Insulin Resistance and Hepatic Steatosis
Heather Basciano,Abigale E. Miller,Mark Naples,Christopher Baker,Rita Kohen,Elaine Xu,Qiaozhu Su,Emma M. Allister,Michael B. Wheeler,Khosrow Adeli +9 more
TL;DR: Dietary cholesterol appears to induce hepatic cholesterol ester and triglyceride accumulation, and diet-induced LXR activation (via cholesterol-derived oxysterols) may possibly be one key underlying mechanism.
101
GLP-1 receptor agonism ameliorates hepatic VLDL overproduction and de novo lipogenesis in insulin resistance.
Jennifer Taher,Christopher Baker,Carmelle Cuizon,Hassan Masoudpour,Rianna Zhang,Sarah Farr,Mark Naples,Celine Bourdon,Zdenka Pausova,Khosrow Adeli +9 more
TL;DR: Exendin-4 prevents fructose-induced dyslipidemia and hepatic VLDL overproduction in insulin resistance through an indirect mechanism involving altered energy utilization, decreased hepatic lipid synthesis and also requires an intact parasympathetic signaling pathway.
86
Inhibition of sphingolipid synthesis improves dyslipidemia in the diet-induced hamster model of insulin resistance: evidence for the role of sphingosine and sphinganine in hepatic VLDL-apoB100 overproduction.
Mark J. Dekker,Christopher Baker,Mark Naples,Josh Samsoondar,Rianna Zhang,Wei Qiu,Jennifer Sacco,Khosrow Adeli +7 more
TL;DR: Inhibition of sphingolipid synthesis can reduce circulating VLDL in hamsters and improve circulating lipids--an effect that is possibly due to improved insulin signaling and reduced lipogenesis but is independent of changes in inflammation.
65